Abiraterone acetate for Congenital Adrenal Hyperplasia (ARCH Trial)

"Eligible patients for this clinical trial must have adrenogenital syndrome and be aged between 2-9. Up to 54 total participants will be accepted into the study."

"Abiraterone acetate was first studied in 1995 at National Institutes of Health Clinical Center. As of now, 18542 studies have been completed with 166 more currently underway. The majority of these active trials are taking place in Los Angeles, California."

"As of December 17th, 2021 this specific trial is no longer recruiting patients. It was first posted on January 1st, 2023. If you're looking for other trials, there are presently 145 studies actively enrolling participants with adrenogenital syndrome and 166 trials for Abiraterone acetate admitting patients."

"As of right now, this trial is not recruiting patients. The listing for this clinical study was first posted on January 1st 2023 and was last edited December 17th 2021. If you are interested in other studies, there are 145 trials actively enrolling participants with adrenogenital syndrome and 166 for Abiraterone acetate that still need patients."

"As specified in the eligibility requirements, patients between 2 and 9 years old may enroll in this clinical trial."

"4 clinical sites are enrolling patients for this study, which include locations such as Children's Hospital of Los Angeles and University of Michigan. Other centres where you can participate in the trial are located in Dallas, amongst 3 other cities."

"Abiraterone acetate is still in Phase 2 of clinical trials, so there is only anecdotal evidence supporting its safety."

"Abiraterone acetate is commonly used to treat ulcerative colitis. Additionally, this medication can be helpful for patients with crohn disease, varicella-zoster virus acute retinal necrosis, and malignant neoplasms."